Skip to main content
Home

Call IconQuestions?
Call 1-833-256-2748

Top navigation

  • Important Safety Information
  • Full Prescribing Information
  • Visit Patient Site
  • Start Form
  • Connect with a Rep
  • Sign Up for Updates
  • ISI
  • PI

User account menu

  • Log in

Main navigation

  • Visit Patient Site
  • Home
  • About hATTR
    Amyloidosis
    • Clinical Presentation
    • Impact on Patients
  • How ONPATTRO
    Works
    • How ONPATTRO Works
    • Pharmacodynamics
  • Clinical
    Data
    • Study Design
    • Polyneuropathy
    • Quality of Life
    • Additional Endpoints
  • Safety
     Profile
  • Dosing &
    Administration
    • Dosing & Preparation
    • Administration
    • Dosing Guide
    • Infusion Center Directory
  • Support &
    Resources
    • Alnylam Assist™
    • Resource Library
    • Access & Reimbursement
  • Getting
    Started
  • Important Safety Information
  • Full Prescribing Information
  • Start Form
  • Connect with a Rep
  • Sign Up for Updates
sky hero image

Site Map

Home

About hATTR Amyloidosis

Clinical Presentation

Impact on Patients

How ONPATTRO Works

How ONPATTRO Works

Pharmacodynamics

Clinical Data

Study Design

Polyneuropathy

Quality of Life

Additional Endpoints

Safety Profile

Dosing & Administration

Dosing & Preparation

Administration

Dosing Guide

Infusion Center Directory

Support & Resources

Alnylam Assist™

Resource Library

Access & Reimbursement

Getting Started

Important Safety Information

Sign Up for Updates

Privacy Policy

Legal Notice

Contact Us

branch

Important Safety Information

Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO® (patisiran). In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.

Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).

Indication

ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about ONPATTRO, please see the full Prescribing Information.

Important Safety Information  

Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO® (patisiran). In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.

Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).

Indication

ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about ONPATTRO, please see the full Prescribing Information.

 

ONPATTRO is a registered trademark, and Alnylam Assist is a trademark, of Alnylam Pharmaceuticals, Inc.
© 2019 Alnylam Pharmaceuticals, Inc. All rights reserved. This site is intended for US audiences.

Footer menu

  • Privacy Policy
  • Legal Notice
  • Contact Us
  • Site Map

You are now leaving onpattrohcp.com.

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed »
Sign up to stay informed »

You are now leaving onpattrohcp.com.

You are now being directed to another Alnylam website.

Proceed »
Sign up to stay informed »

You are now leaving ONPATTRO.com.

The information contained in this section of the site is intended for US healthcare professionals only.

click CONTINUE if you are a healthcare professional

Continue

The safety and effectiveness of ONPATRO™ (patisiran) were evaluated in a placebo-controlled trial of 225 patients with hATTR amyloidosis. This means some patients received a placebo that did not contain medication. the effects of ONPATTRO were evaluated against the effects of placebo. This study was the largest controlled study of hATTR amyloidosis.

The site you are about to enter is intended for US healthcare professionals. Please confirm that you are a US healthcare professional.

I am not a
healthcare professional »